Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.

Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.

Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.

Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.

Abstract: A system having an annotation module that annotates, using a master ontology, unstructured verbatim regarding a product and related issue, and a customer-observable (CO) construction module determining associations amongst terminology in the annotated output, yielding a group of CO pairs. A CO merging module merges at least one first CO pair into a second CO pair based on similarities. A pointwise mutual-information module determines which CO pairs of the group of merged CO pairs are relatively more-severe or more-relevant, yielding a group of critical CO pairs. An output module initiates activity to implement the results, such as by automated repair of the product or change to product design or manufacturing process. The system in some embodiments identifies, using a subject-matter-expert (SME) database, features of false-positive associations, and in machine-learning implements the features to improve CO formation going forward.

Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.

Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.

Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

Abstract: A warranty database stores service repair verbatims. An ontology database that specifies relationships between service terms includes linking relationships between vehicle terminology and cluster categories. The ontology database is reconfigurable for allowing a user to add, delete, and modify contents within the ontology database. A verbatim extraction tool extracts service repair verbatims from the warranty database as function of user selected parameters and a user selected ontology. The user selected ontology is a subset of the ontology database. The service verbatims are segregated into a plurality of cluster categories as a function of the selected parameters and the user selected ontology. A report generating device selectively generated reports based on segregating service verbatims into a plurality of cluster categories.

Abstract: A method of odor control comprising applying a urea formaldehyde polymer additive to manure in an amount sufficient to reduce or eliminate odor, wherein the polymer optionally contains NBPT and/or DCD, where the polymer can be a dry solid, or it can be suspended in a liquid and applied to unmanipulated liquid or solid manure.

Abstract: A method is provided for detecting trends in service repairs for vehicles. Service repair verbatims are accessed from a warranty database that includes information relating to an identified concern with the vehicle. A thesaurus of service repair related terms is provided. The service repair related terms are each associated with at least one of a component category, a concern category, a cause category, and a correction of repair category. Key terms are identified in each service repair verbatim that have an association with the service repair related terms in the thesaurus. The key terms are extracted from each of the service repair verbatims. A user selectively generates a report based on a key term in the component category and at least one other key term from at least one other category. The report identifies an aggregate number of service repair verbatims associated with the key terms selected by the user.

Abstract: A method is provided for detecting trends in service repairs for vehicles. Service repair verbatims are accessed from a warranty database that includes information relating to an identified concern with the vehicle. A thesaurus of service repair related terms is provided. The service repair related terms are each associated with at least one of a component category, a concern category, a cause category, and a correction of repair category. Key terms are identified in each service repair verbatim that have an association with the service repair related terms in the thesaurus. The key terms are extracted from each of the service repair verbatims. A user selectively generates a report based on a key term in the component category and at least one other key term from at least one other category. The report identifies an aggregate number of service repair verbatims associated with the key terms selected by the user.

Abstract: Compounds that bind cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The compounds are mimetics of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABOLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these compounds for therapeutic, diagnostic and assay purposes.

Abstract: A method of odor control comprising applying a urea formaldehyde polymer additive to manure in an amount sufficient to reduce or eliminate odor, wherein the polymer optionally contains NBPT and/or DCD, where the polymer can be a dry solid, or it can be suspended in a liquid and applied to unmanipulated liquid or solid manure.

Abstract: Compounds that bind cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The compounds are mimetics of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABOLO, IIid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these compounds for therapeutic, diagnostic and assay purposes.

Abstract: Compounds that bind cellular IAPs (inhibitor of apoptosis proteins) are disclosed. The compounds are mimetics of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABOLO, IIid. Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these compounds for therapeutic, diagnostic and assay purposes.

Abstract: Assays are disclosed for identifying peptides and peptidomimetics for promoting apotosis in cells, through a pathway involving the Inhibitor of Apoptosis Proteins (IAPs), exemplified by XIAP, and the mitochondrial protein Smac/DIABOLO (hereinafter Smac) and homologs thereof. Also disclosed are IAP-binding peptides and peptidomimetics identified through the use of the assay.